A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00318136|
Recruitment Status : Completed
First Posted : April 26, 2006
Results First Posted : April 6, 2010
Last Update Posted : May 11, 2010
|Condition or disease||Intervention/treatment||Phase|
|Non-small Cell Lung Cancer||Drug: Bevacizumab Drug: Carboplatin Drug: Paclitaxel||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||47 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer|
|Study Start Date :||September 2005|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||July 2009|
|Experimental: Treated with Bevacizumab||
15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
- Incidence of Grade ≥3 Pulmonary Hemorrhage Adverse Events [ Time Frame: First bevacizumab administration until 60 days after discontinuation of bevacizumab or death ]To estimate the rate of National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE), Version 3.0, Grade ≥3 pulmonary hemorrhage adverse events. Per NCI CTCAE v.3: "Grade 3 = Transfusion, interventional radiology, endoscopic, or operative intervention indicated; radiation therapy (i.e., hemostasis of bleeding site); Grade 4 = Life-threatening consequences; major urgent intervention indicated; Grade 5 = Death."
- Selected Adverse Events [ Time Frame: First bevacizumab administration until 60 days after discontinuation of bevacizumab or death ]
Selected treatment-emergent adverse events for any grade of pulmonary hemorrhage, any grade of non-pulmonary hemorrhage, any grade of gastrointestinal perforation, Grade ≥ 2 arterial thromboembolic events, Grade ≥ 2 left ventricular systolic dysfunction, Grade ≥ 3 proteinuria, and Grade ≥ 3 hypertension. Refer to NCI CTCAE v.3 for grading definitions.
Serious adverse events (SAEs) occurring in any of the above categories are included. See the Serious Adverse Events section below for full SAE reporting.
- Adverse Events That Led to Discontinuation of Bevacizumab [ Time Frame: First bevacizumab administration until 60 days after discontinuation of bevacizumab or death ]Any treatment-emergent adverse event leading to study treatment discontinuation
- Progression-free Survival [ Time Frame: Length of study ]
Progression−free survival (PFS) was defined as the time from enrollment to the time of documented disease progression or death from any cause, whichever occurred earlier. PFS was determined for only those patients that received bevacizumab.
Summary of PFS (median) was estimated from Kaplan−Meier curve. The 95% confidence interval (CI) for the median was computed using the method of Brookmeyer and Crowley.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00318136
|Study Director:||Leonardo Faoro, M.D.||Genentech, Inc.|